Abstract:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. FGFR4 has been implicated in HCC progression, making it a promising therapeutic target. We introduce an approach for identifying novel FGFR4 inhibitors by sequentially adding fragments to a common warhead unit. This strategy resulted in the discovery of a potent inhibitor, 4c , with an IC 50 of 33 nM and high selectivity among members of the FGFR family. Although further optimisation is required, our approach demonstrated the potential for discovering potent FGFR4 inhibitors for HCC treatment, and provides a useful method for obtaining hit compounds from small fragments.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to discover new FGFR4 inhibitors for the treatment of hepatocellular carcinoma (HCC). Specifically, the authors start from a common warhead unit and gradually construct small - molecule inhibitors that can effectively bind to FGFR4 through a build - up fragment strategy. This method aims to increase the possibility of discovering highly effective FGFR4 inhibitors and provides an effective way to obtain hit compounds from small fragments. ### Background - **Hepatocellular carcinoma (HCC)**: It is the most common type of primary liver cancer and was the sixth - leading cause of cancer - related death worldwide in 2022. - **FGFR4**: Fibroblast Growth Factor Receptor 4 (FGFR4) plays an important role in the progression of HCC. Aberrant expression or dysregulation of FGFR4 is associated with the development and progression of multiple solid tumors, including liver cancer, lung cancer, and breast cancer. - **Existing therapies**: Although multi - kinase inhibitors (such as sorafenib and regorafenib) currently used for advanced HCC have significantly improved the survival rate and quality of life of patients, the median survival time is still less than one year. ### Research objectives - **Discover new FGFR4 inhibitors**: Start from a small and commonly - used warhead unit and gradually construct FGFR4 inhibitors with high selectivity and high activity through a step - by - step fragment - adding method. - **Verify the effectiveness of the method**: Demonstrate the potential of this method in discovering highly effective FGFR4 inhibitors and provide a practical method for obtaining hit compounds from small fragments. ### Main results - **Discover an effective inhibitor**: A new FGFR4 inhibitor named 4c was discovered through this strategy, with an IC50 value of 33 nM and high selectivity among FGFR family members. - **Potential for further optimization**: Although further optimization is required, this method shows the potential for discovering highly effective FGFR4 inhibitors, providing new hope for the treatment of HCC. ### Conclusion This study successfully discovered highly effective FGFR4 inhibitors through the step - by - step fragment - adding method, providing new candidate drugs for the treatment of HCC. At the same time, this method also provides an effective way to obtain hit compounds from small fragments.

Discovery of novel FGFR4 inhibitors through a build-up fragment strategy

Discovery of Novel 7-Azaindole Derivatives As Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma

Discovery of 1,6-Naphthyridin-2(1 H )-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma

Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma

Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity

Discovery of a Novel FGFR4 Selective Inhibitor Via Structure-Activity Relationship Studies of FGF401

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

Structure-based design of a dual-warhead covalent inhibitor of FGFR4

Design, Synthesis, and Anticancer Evaluation of Arylurea Derivatives As Potent and Selective Type II Irreversible Covalent FGFR4 Inhibitors

Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer.

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4

Discovery of Ureido-Substituted 4-Phenylthiazole Derivatives as IGF1R Inhibitors with Potent Antiproliferative Properties

Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors

Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants

Discovery of Potent, Orally Active Compounds of Tyrosine Kinase and Serine/Threonine-Protein Kinase Inhibitor with Anti-Tumor Activity in Preclinical Assays

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects

Discovery and development of quinazoline compounds as irreversible pan-fibroblast growth factor receptor inhibitors with potent antitumor activities

Design, Synthesis, and Biological Evaluation of Quinazoline Derivatives with Covalent Reversible Warheads As Potential FGFR4 Inhibitors